|
|
 |
|
Viewing report
|
|
|
|
Treatment Algorithms 2001: Prostate Cancer
Datamonitor, Dec 2001
For over a decade, total androgen blockade has been considered by some quarters of prostate cancer specialists to be the gold-standard treatment. However, in recent years, the trend has been moving towards the use of less aggressive hormonal monotherapy. This represents a significant opportunity for existing hormonal agents, especially AstraZeneca''s Casodex, when its imminent approval for monotherapy use is expected to change the landscape of prostate cancer treatment. This report provides in-depth analysis of the current and future trends in the treatment of prostate cancer and enables you to: * Maximize your sales forecasts and future product positioning through identification the key drivers that affect the prescription of current products in the market for prostate cancer treatment * Strengthen your marketing strategy and market penetration based on comprehensive knowledge of the current treatment patterns in the US, Japan, Germany, France, Spain, Italy and the UK * Expose potential threats to your business through analysis of key future trends in the management of prostate cancer
Customers who bought this item also bought
Stakeholder Insight: Prostate Cancer - Hormone-Refractory Patients Still Waiting For Treatment Breakthroughs
Strategic Perspectives: Prostate Cancer - Issues in Second-line, Brachytherapy and Hormone-Refractory Prostate Cancer Treatments
Stakeholder Insight: Prostate Cancer Treatment in the USA
Stakeholder Insight: Metastatic And Hormone Refractory Prostate cancer
Treatment Algorithms 2001 Breast Cancer: Herceptin Falling into Stride
Stakeholder Insight: Prostate Cancer Treatment and Commercial Issues
Stakeholder Insight: Local and Locally Advanced Prostate Cancer
Drugs of Tomorrow 2000: Prostate Cancer - Hormonals and Beyond
Cancer Drug Discoveries: What the Future Holds: Prostate Cancer Chapter
Prostate Cancer Therapeutics - Global Strategic Business Report
Prostate Cancer Insight - Profiting From Changing Treatment Patterns
Prostate Cancer - A Therapeutic & Competitive Insight
|
|
|
|
